Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls. Those treated with sulphonylurea had markedly reduced survival compared with both matched controls and those receiving metformin monotherapy. This supports the position of metformin as first-line therapy and implies that metformin may confer benefit in non-diabetes. Sulphonylurea remains a concern.

Growth factors are important for wound healing because they regulate key cellular functions. However, in diabetic wounds, these growth factors are rapidly broken down by other enzymes known as proteases. This dramatically slows down wound recovery. At the same time, diabetic wounds are characterised by persistently high levels of inflammation. We wanted to tackle these two issues by using microneedles for both delivery and extraction. It is minimally invasive, can be fabricated with precision, and allows for the active compounds to be painlessly administered directly into wounds. Microneedle patches are excellent materials for wound healing.

Companies like Dexcom and Insulet have been working to expand the reach of their devices from Type 1 diabetes into Type 2, which would include millions of people in the U.S.

Over about 3.5 years, Al-Aly and his colleagues tracked more than 200,000 people with diabetes on GLP-1 drugs and about 1.7 million people with diabetes using other blood-sugar-lowering medications. They tracked the effects of GLP-1 drugs on 175 health conditions. Compared with other diabetes medications, GLP-1 drugs were linked to a lower risk of dozens of conditions, including heart disease, stroke and kidney disease. They also lowered the risk of psychotic disorders by 18%, Alzheimer’s disease by 12%, and addiction disorders by an average of 13%.

An observational study of patients with type 2 diabetes treated for coronary artery disease with second-generation drug-eluting stents (DESs) has found a significant association between poor glycaemic control and a higher risk of stent failure driven by in-stent restenosis.

I can explain that I prescribed a glucagon-like peptide 1 (GLP-1) receptor agonist because the patient had diabetes and was overweight, and multiple studies show that this class of drug leads to weight loss and reduced mortality risk. But then I get the follow-up: Sure, but why THAT GLP-1 drug? Why did you pick semaglutide (Ozempic) over tirzepatide (Mounjaro)? Here's where I run out of good answers. Sometimes I choose a drug because that's what the patient's insurance has on their formulary. Sometimes it's because it's cheaper in general. Sometimes, it's just force of habit. I know the correct dose, I have experience with the side effects — it's comfortable.

In June, the FDA released a warning about the new antiobesity medications, stating it had received reports of adverse events after people self-administered semaglutide from a compounding pharmacy. The warning also states that compounding pharmacies may be selling salt forms of the active ingredient, including semaglutide sodium and semaglutide acetate, though the FDA is not aware of any basis for compounding a drug using semaglutide salts that would meet federal requirements.

Health experts urge women not to use Ozempic or similar drugs to increase fertility, due to increased risks of birth defects and miscarriage.

Deux nouveaux médicaments qui permettent de ralentir la progression, à son stade précoce, du diabète de type 1, font l'objet d'une publication récente dans une revue médicale anglaise. Des médicaments pas encore disponibles sur le marché français, pour une maladie qui touche plus de 250.000 personnes dans notre pays.

WeightWatchers' new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7. 

The work is based on an invention by Minglin Ma of Cornell who conceived of a detachable polymer thread containing thousands of islet cells covered by a thin hydrogel covering that could be inserted into a patient's belly without inducing an immune reaction. Shapiro was already working on a diabetes skin implant with similar qualities and upon stumbling on Ma’s work had the idea of combining the two approaches. This proved very successful. “And indeed it worked! By combining the two, it really did improve the skin site for engrafting cells without the need for anti-rejection drugs. The data are very compelling,”.

In a revolutionary step forward, researchers have 3D printed a biohybrid microstructure designed specifically for diabetes treatment. This innovation, stemming from a collaboration between the KTH Royal Institute of Technology and Karolinska Institutet, introduces a medical microdevice intended for the human eye, providing a fresh road for cell-based medical treatments for the rising global population affected by diabetes type 1 and 2. To achieve this, the team utilized Nanoscribe‘s 3D printing technology and materials.

Novo Nordisk recherche des solutions qui reposent sur des technologies à la pointe et des approches créatives pour adresser les challenges associés au diabète et à ses complications. Avez-vous des solutions innovantes pour soutenir les patients dans le diagnostic et la prise en charge de leur diabète et de ses complications ? Alors ce concours est fait pour vous!

Work, family, and other responsibilities can take up so much time that it gets hard to focus on eating healthy, exercising, and losing weight. If you have diabetes, balancing out life and wellness can become a real issue. Klinio diabetes app was designed to reflect the needs of people who want to fight diabetes but can hardly find the time. It’s not your typical app. It’s a virtual assistant and app for people with diabetes that offers advanced features to help you take better care of diabetes.

The study, conducted over a five-year period and involving a large cohort of participants, analyzed the medical records of over 50,000 individuals. The researchers discovered that those who had been taking low-dose aspirin on a daily basis had a 20% higher risk of developing diabetes compared to those who did not take aspirin.

The goal of this secret endeavor — dubbed E5 — is to measure how much glucose is in someone’s body without needing to prick the skin for blood. After hitting major milestones recently, the company now believes it could eventually bring glucose monitoring to market, according to people familiar with the effort.

Les fabricants d’insuline ont coutume d’indiquer que les flacons non ouverts d’insuline doivent être conservés au réfrigérateur à une température comprise entre 2°C et 8°C et qu’un flacon déjà ouvert ne doit pas être exposé à des températures supérieures à 25°C-30°C pendant sa durée d’utilisation qui, selon le produit, peut varier de dix jours à huit semaines. Les fabricants recommandent de se débarrasser de l’insuline sortie du réfrigérateur pendant une période spécifiée, que le flacon ait été déjà ouvert ou non et pas encore utilisé. Pour la majorité des produits, ce délai est de quatre semaines.

People with diabetes must consume beer with caution. Read on to know more about the relationship between beer and diabetes.

A glucose sensor is placed under the skin to automatically calculate, with an algorithm, how much insulin to deliver via a pump. This means people with type 1 diabetes no longer have to closely monitor levels of sugar in their blood manually and take daily injections. They can also monitor readings on their smartphones through a system where they upload the number of carbohydrates estimated to be consumed during a meal.

Clinical depression is associated with poorer adherence to hypoglycaemic medication in patients with diabetes mellitus, leading to poorer glycaemic control, diabetes management, and increased complications. The main aim of the TELE-DD trial was to demonstrate the efficacy of a proactive and psychoeducational telephonic intervention based on motivational interviewing and collaborative care to reduce nonadherence and improve prognosis in individuals with diabetes mellitus and concurrent depression.